A2A adenosine receptor protects tumors from antitumor T cells

By A. Ohta, E. Gorelik, S. Prasad, F. Ronchese, D. Lukashev, M. Wong, Xiaojun Huang, Sheila Caldwell, Kebin Liu, Patrick T. Smith and 5 more. Proceedings of the National Academy of Sciences of the United States of America, 2006

1,017 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/6206d9b8dcfc5f9d49245e1a1d6c44b4212afbe4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. V. Kuchroo
2. M. Oukka
3. Vito Pistoia
4. Peter Vandenabeele
5. F. Di Virgilio
6. D. Cua
7. W. E. Paul
8. Jinfang Zhu

In Oncology

1. V. Kuchroo

In Physiology

1. B. Fredholm
2. F. Di Virgilio
3. S. Robson

Citations in the corpus

• Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase (2008, background): “Recent data show that solid tumours have a gradient of adenosine concentration from the centre to the periphery, higher than the surrounding healthy tissue [6].”
• Adenosine, an endogenous distress signal, modulates tissue damage and repair (2007, background): “This fact combined with the known ability of adenosine to reduce IFNg production via A2A (and A2B) receptors provided a good explanation for the altered tumor growth.(68) Another contributing factor, which was covered before, is that A2A receptors are involved in angiogenesis.”
• Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression (2007, background): “Modulation of infl ammation by adenosinergic mechanisms has been rigorously tested in models of T cell–dependent autoimmune and viral hepatitis (21) and in antitumor T cell immunity (22).”
• Immunity, inflammation and cancer: a leading role for adenosine (2013, neutral): “APCP, adenosine 5ʹ-(α,β-methylene) diphosphate; ARL67156, 6-N,N-diethyl-D-β,γ dibromomethylene A TP; Cl-IB-MECA, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofu ranuronamide; CTLA4, cytotoxic T lymphocyte-associated antigen 4; IB-MECA,1-deoxy-1-[6-[[(3-iodopheny”
• Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions (2023, background): “Hyperoxia treatment suppressed the expressions of adenosine, an immunosuppressive factor,(235) and reactive nitrogen production,(236) and increased IFN-γ levels and perforin granules.(237) Sustained hypoxic stimulation induces mitochondrial stress, resulting in the loss of mitochondrial functions, e”